On Thursday, ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)’s shares showed no change to $12.90.
ZIOPHARM Oncology, Inc. (ZIOP) a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer. Its synthetic immuno-oncology programs, in partnership with Intrexon Corporation and the MD Anderson Cancer Center, comprise chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use both non-viral and viral gene transfer methods for broad scalability.
Thompson Creek Metals Company Inc (USA) (TC) declared recently an update on mill operations and throughput at Mount Milligan Mine. Over the past few months, various adjustments and modifications were made at Mount Milligan to address operational challenges practiced during the first quarter of 2015. While additional improvements are predictable to be accomplished in the second half of this year, during the month of May, daily mill throughput averaged 50,686 tonnes, and tonnage per operating hour averaged 2,198, contrast to 39,569 tonnes and 1,889 tonnes per hour, respectively, for the first quarter of 2015. Mill availability in May was about 96%, contrast to 87% in the first quarter.
ZIOPHARM Oncology, Inc., a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer. Its synthetic immuno-oncology programs, in partnership with Intrexon Corporation and the MD Anderson Cancer Center, comprise chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use both non-viral and viral gene transfer methods for broad scalability.
Novavax, Inc. (NASDAQ:NVAX)’s shares gained 1.42% to $12.11.
Novavax, Inc. (NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, recently declared the appointment of Gail K. Boudreaux to its Board of Directors.
Ms. Boudreaux most recently served as the Executive Vice President of UnitedHealth Group from May 2008 until February 2015 and was the Chief Executive Officer of UnitedHealthcare from January 2011 to November 2014. Her extensive experience comprises more than 30 years of service across a broad spectrum of health care operations. Ms. Boudreaux is presently a director of Zimmer Holdings, Inc. and Xcel Energy Inc. and a trustee of Dartmouth College. Ms. Boudreaux holds a Master of Business Administration degree in finance and health care administration from the Columbia Business School and a bachelor’s degree in psychology from Dartmouth College. She has been honored as one of Fortune’s 50 Most Powerful Women in American Business for the last six years and was recognized by Modern Healthcare as one of the Top 25 Women in Healthcare.
Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline comprises respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase II clinical trials, in addition to pediatric respiratory syncytial virus candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase I clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, in addition to combination respiratory vaccine candidate, which is pre-clinical trial; and seasonal influenza vaccine candidate that is Phase III clinical trial, in addition to rabies G protein vaccine candidate, which is in Phase 1/2 clinical trial.
At the end of Thursday’s trade, LKQ Corporation (NASDAQ:LKQ)‘s shares dipped -0.10% to $31.34.
LKQ Corporation (LKQ) has again been named to the Fortune 500 list, Fortune magazine’s annual ranking of America’s largest companies by revenue. LKQ had 2014 total revenue of $6.7 billion. Fortune magazine ranked LKQ No. 403 on its list contrast to No. 490 last year.
LKQ Corporation, together with its auxiliaries, distributes replacement parts, components, and systems used in the repair and maintenance of vehicles in the United States, the United Kingdom, the Netherlands, Belgium, Northern France, Canada, Mexico, and Central America. The company operates in four segments: Wholesale North America, Wholesale Europe, Self Service, and Specialty. It distributes various products, counting aftermarket collision and mechanical products; recycled collision and mechanical products; and refurbished collision replacement products, such as wheels, bumper covers and lights, and remanufactured engines.
Abbott Laboratories (NYSE:ABT), ended its Thursday’s trading session with -0.57% loss, and closed at $50.77.
Abbott (ABT) declared that it has reached a contract to purchase Tendyne Holdings, Inc., a private medical device company focused on developing minimally invasive mitral valve replacement therapies. Under the terms of the agreement, Abbott will acquire the equity of Tendyne that it does not already own for $225 million upfront, resulting in a total transaction value of $250 million, plus potential future payments tied to regulatory milestones.
Tendyne’s Bioprosthetic Mitral Valve System is an investigational device and not presently accessible for sale. The U.S. Food and Drug Administration has offered approval for a feasibility clinical trial to provide data about the device’s safety and effectiveness. The trial has begun enrolling patients, and there are plans to start enrollment next year in a clinical trial to support CE Mark in Europe.
Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome; intrahepatic cholestasis or depressive symptoms; gynecological disorders; dyslipidemia; hypertension; hypothyroidism; pain, fever, and inflammation; hormone replacement therapy; anti-infective and influenza vaccines; and product that regulates physiological rhythm of the colon.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
